Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of 18.58% is 92% above its 5-year average of 9.69%, near the high end of its 5-year range (-88.02%–21.16%).
0.88% below its 12-month average of 18.74%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-27): 19.63%.
EBITDA MARGIN
18.58%
EBITDA MARGIN AVG TTM
18.74%
EBITDA MARGIN AVG 3Y
15.36%
EBITDA MARGIN AVG 5Y
9.69%
EBITDA MARGIN AVG 10Y
12.29%
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-0.88%
CURRENT VS 3Y AVG
+20.94%
CURRENT VS 5Y AVG
+91.65%
CURRENT VS 10Y AVG
+51.15%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Market Cap
$921.45M
EBITDA Margin
20.95%
TTM Avg
21.20%
3Y Avg
20.44%
5Y Avg
19.67%
Market Cap
$922.50M
EBITDA Margin
-189.51%
TTM Avg
-701.94%
3Y Avg
-497.69%
5Y Avg
-575.23%
Market Cap
$903.13M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$942.78M
EBITDA Margin
-448.41%
TTM Avg
-402.69%
3Y Avg
-402.69%
5Y Avg
-402.69%
Market Cap
$943.26M
EBITDA Margin
-64.07%
TTM Avg
-61.50%
3Y Avg
-81.15%
5Y Avg
-81.15%
Market Cap
$867.60M
EBITDA Margin
-37.08%
TTM Avg
-66.80%
3Y Avg
-66.80%
5Y Avg
-66.80%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Bioventus Inc. (BVS) | $915.95M | 18.58% | 18.74% | 15.36% | 9.69% |
| HealthStream, Inc. (HSTM)vs › | $921.45M | 20.95% | 21.20% | 20.44% | 19.67% |
| Arbutus Biopharma Corp (ABUS)vs › | $922.50M | -189.51% | -701.94% | -497.69% | -575.23% |
| Corvus Pharmaceuticals, Inc. (CRVS)vs › | $903.13M | N/A | N/A | N/A | N/A |
| Kura Oncology, Inc. (KURA)vs › | $942.78M | -448.41% | -402.69% | -402.69% | -402.69% |
| CeriBell, Inc. (CBLL)vs › | $943.26M | -64.07% | -61.50% | -81.15% | -81.15% |
| Monte Rosa Therapeutics, Inc. (GLUE)vs › | $867.60M | -37.08% | -66.80% | -66.80% | -66.80% |
| Apnimed, Inc. (APMD)vs › | $866.15M | N/A | N/A | N/A | N/A |
| Jade Biosciences, Inc. (JBIO)vs › | $856.30M | N/A | N/A | N/A | N/A |
| Beta Bionics, Inc. (BBNX)vs › | $852.55M | -68.63% | -68.17% | -9114.49% | -9114.49% |
Gross Margin
68.0%
EBITDA Margin
18.6%
Operating Margin
10.6%
Net Margin
9.4%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-27 | 19.63% |
| 2026-03-28 | 15.21% |
| 2025-12-31 | 21.16% |
| 2025-09-27 | 16.95% |
| 2025-06-28 | 20.77% |
| 2025-03-29 | 13.59% |
| 2024-12-31 | 13.27% |
| 2024-09-28 | 11.76% |
| 2024-06-29 | -12.16% |
| 2024-03-30 | 12.91% |
| 2023-12-31 | 10.06% |
| 2023-09-30 | 13.45% |
| 2023-07-01 | 15.58% |
| 2023-04-01 | -63.49% |
| 2022-12-31 | -1.81% |
| 2022-10-01 | -88.02% |
| 2022-07-02 | 6.47% |
| 2022-04-02 | -7.65% |
| 2021-12-31 | 6.55% |
| 2021-10-02 | 6.86% |
| 2021-07-03 | 1.58% |
| 2021-04-03 | 35.68% |
| 2020-12-31 | 12.94% |
| 2020-09-30 | 16.54% |
| 2020-06-30 | 4.58% |
| 2020-03-31 | 25.75% |
| 2019-12-06 | 21.57% |
| 2019-12-06 | 21.84% |
| 2019-06-29 | 10.01% |
| 2019-03-29 | 10.01% |
| 2016-03-31 | 10.85% |
| 2015-03-31 | -14.81% |
